Remarkable response to alectinib for metastatic papillary thyroid cancer with STRN-ALK fusion: A case report

被引：3

作者：

Zhu, Lucheng ^{[1
,2
]}

Ma, Shenglin ^{[1
]}

Xia, Bing ^{[1
,3
]}

机构：

[1] Zhejiang Univ, Affiliated Hangzhou Canc Hosp, Dept Thorac Oncol, Sch Med, Hangzhou, Peoples R China

[2] Zhejiang Chinese Med Univ, Affiliated Hangzhou Canc Hosp, Dept Oncol, Hangzhou, Peoples R China

[3] Zhejiang Univ, Canc Ctr, Hangzhou, Peoples R China

来源：

FRONTIERS IN ONCOLOGY | 2022年 / 12卷

关键词：

ALK inhibitor; STRN-ALK fusion; thyroid cancer; alectinib; case report; VARIANT;

D O I：

10.3389/fonc.2022.1009076

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Little is known about the efficacy of alectinib for papillary thyroid cancer with STRN-ALK fusion. A 64-year-old female presented with metastatic papillary thyroid cancer, widespread to lungs, mediastinal lymph nodes and brain 20 years after surgery. Disease progression still occurred after radioactive iodine therapy, chemotherapy, and radiotherapy. Tissue obtained from left cervical lymph node confirmed metastatic papillary thyroid cancer. Molecular profiling from re-biopsy tissue identified an STRN-ALK fusion rearrangement. After multidisciplinary discussion, alectinib was administered to the patient. Treatment was well tolerated, and follow-up images confirmed a partial response. ALK occurs rarely, with limited data suggesting the efficacy of ALK inhibitors in thyroid cancer. We presented the first case of a patient with PTC and STRN-ALK fusion to be treat effectively with alectinib.

引用

页数：4

共 50 条

[31] Metastatic rectal cancer to papillary thyroid carcinoma: a case report and review of literature
Min Luo
Yu Huang
Yongqiang Li
Yumei Zhang
[J]. BMC Gastroenterology, 20
[32] Complete diaphysis resorption of the femur: A case report in a metastatic papillary thyroid cancer
Suwardjo, Suwardjo
Avanti, Widya Surya
Dwianingsih, Ery Kus
Harahap, Wirsma Arif
Anwar, Sumadi Lukman
[J]. ANNALS OF MEDICINE AND SURGERY, 2020, 60 : 614 - 618
[33] Metastatic rectal cancer to papillary thyroid carcinoma: a case report and review of literature
Luo, Min
Huang, Yu
Li, Yongqiang
Zhang, Yumei
[J]. BMC GASTROENTEROLOGY, 2020, 20 (01)
[34] Papillary thyroid carcinoma metastatic to the pancreas: Case report
Cho, Margaret
Acosta-Gonzalez, Gabriel
Brandler, Tamar C.
Basu, Atreyee
Wei, Xiao-Jun
Simms, Anthony
[J]. DIAGNOSTIC CYTOPATHOLOGY, 2019, 47 (03) : 214 - 217
[35] Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1–ALK fusion: a case report
Kazunori Honda
Shigenori Kadowaki
Kyoko Kato
Nobuhiro Hanai
Yasuhisa Hasegawa
Yasushi Yatabe
Kei Muro
[J]. Investigational New Drugs, 2019, 37 : 791 - 795
[36] Partial treatment response to alectinib in metastatic non-small cell lung cancer with KIDINS220-ALK fusion
Lei, Yanna
Zeng, Shasha
Li, Xiaoyu
Shu, Pei
Wang, Weiya
Wang, Yongsheng
[J]. PRECISION CLINICAL MEDICINE, 2023, 6 (02)
[37] Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report
Honda, Kazunori
Kadowaki, Shigenori
Kato, Kyoko
Hanai, Nobuhiro
Hasegawa, Yasuhisa
Yatabe, Yasushi
Muro, Kei
[J]. INVESTIGATIONAL NEW DRUGS, 2019, 37 (04) : 791 - 795
[38] Case report: Dramatic response to alectinib in a lung adenosquamous carcinoma patient harbouring a novel CPE-ALK fusion
Qin, Yanyan
Li, Fei
Tan, Yuan
Duan, Qianqian
Zhang, Qin
[J]. FRONTIERS IN ONCOLOGY, 2022, 12
[39] Metastatic Large-Cell Neuroendocrine Lung Carcinoma With ALK Fusion Oncogene With Partial Response to Alectinib
Leblanc, Andreanne
Owen, Scott
Fiset, Pierre Olivier
Corrador, Andrea Liliam Gomez
Isenberg, Jordan
Bouganim, Nathaniel
[J]. JCO PRECISION ONCOLOGY, 2021, 5 : 802 - 807
[40] MinocyclineBlack thyroid and papillary thyroid cancer: case report
[J]. Reactions Weekly, 2007, 1164 (1) : 17 - 17

← 1 2 3 4 5 →